ETHZilla Corporation Common Stock (ATNF) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Palo Alto, CA, United States. The current CEO is Lloyd Blair Jordan.
ATNF has IPO date of 2017-06-27, 4 full-time employees, listed on the NASDAQ Capital Marke, a market capitalization of $1.08B.
1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
